TPST
TPST
NASDAQ · Biotechnology

Tempest Therapeutics Inc

$1.73
+0.07 (+4.22%)
Financial Highlights (FY 2026)
Revenue
24.83M
Net Income
-258,165,367
Gross Margin
-166.7%
Profit Margin
-16,993.3%
Rev Growth
D/E Ratio
0.33
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -166.7% 55.6% 55.6% 55.6%
Operating Margin -16,870.0% -19.4% -23.6% -23.4%
Profit Margin -16,993.3% -27.6% -27.4% -21.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 24.83M 4.18M 3.97M 4.44M
Gross Profit -41,381,332 2.32M 2.21M 2.47M
Operating Income -4,188,534,716 -808,931 -937,046 -1,041,926
Net Income -258,165,367 -1,151,363 -1,086,006 -951,664
Gross Margin -166.7% 55.6% 55.6% 55.6%
Operating Margin -16,870.0% -19.4% -23.6% -23.4%
Profit Margin -16,993.3% -27.6% -27.4% -21.4%
Rev Growth +11.5% +10.2% +12.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 2.79M 2.99M 2.87M 2.89M
Total Equity 8.40M 4.14M 4.36M 4.56M
D/E Ratio 0.33 0.72 0.66 0.63
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -256,894,157 -1,394,086 -1,159,340 -1,348,527
Free Cash Flow -921,744 -1,324,564 -1,179,947